Estimating the Prevalence of Recreational Opioid Use in Spain Using a Multiplier Method.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
15 04 2022
Historique:
received: 15 02 2022
revised: 07 04 2022
accepted: 12 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 27 4 2022
Statut: epublish

Résumé

Acknowledgement of the prevalence of recreational opioid use (PROU) is key to the planning and evaluation of care services. However, in Spain, the prevalence of PROU in recent years is unknown. The objective of this study was to estimate the PROU between 2005 and 2019 in the general populations of six Spanish cities. A benchmark-multiplier methodology was used to estimate the PROU population size. The benchmark used was overdose deaths from recreational opioid use in Spain's six most populated cities. The multiplier was the overdose death rate in a cohort of heroin users. Linear regression was used to estimate the trend of the PROU estimate over the set period of years. In 2005, the PROU was 4.78 (95%CI 3.16-7.91) per 1000 people. The estimated trend decreased, with the two lowest values being 2.35 per 1000 in 2015 and 2.29 in 2018. In 2019 the PROU was 2.60 per 1000 (95%CI 1.72-4.31), 45% lower than in 2005. While the decline in the PROU continues, its deceleration over the last four years calls for increased vigilance, especially in light of the opioid crisis in North America that has occurred over the last few years.

Identifiants

pubmed: 35457681
pii: ijerph19084815
doi: 10.3390/ijerph19084815
pmc: PMC9027743
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Acción Estratégica en Salud (AES), project AES PI19/00982
ID : PI19/00982

Références

NIDA Res Monogr. 1977 Nov;16:15-22
pubmed: 97549
Addiction. 2009 Feb;104(2):248-55
pubmed: 19149821
Gac Sanit. 2007 Sep-Oct;21(5):397-403
pubmed: 17916304
BMC Med Res Methodol. 2013 Jan 14;13:4
pubmed: 23317002
Eur J Pain. 2021 May;25(5):1072-1080
pubmed: 33428812
Eur Addict Res. 2015;21(6):300-6
pubmed: 26022713
Sci Total Environ. 2017 Dec 31;609:916-926
pubmed: 28783904
Emergencias. 2018 Dic;30(6):385-394
pubmed: 30638341
J Subst Abuse Treat. 2021 Mar;122:108229
pubmed: 33509418
Addict Behav. 2017 May;68:35-38
pubmed: 28088741
Curr Med Res Opin. 2020 Feb;36(2):285-291
pubmed: 31635485
Am J Epidemiol. 1995 Mar 15;141(6):567-74
pubmed: 7900724
Clinicoecon Outcomes Res. 2015 Sep 15;7:477-88
pubmed: 26396536
J Subst Abuse Treat. 2013 Jul;45(1):19-30
pubmed: 23462151
Eur J Public Health. 2011 Oct;21(5):646-8
pubmed: 20551045
Drug Alcohol Depend. 2020 Dec 1;217:108367
pubmed: 33153831
Rev Esp Salud Publica. 2006 Sep-Oct;80(5):505-20
pubmed: 17193814

Auteurs

José Pulido (J)

Departamento de Salud Pública y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Albert Sanchez-Niubo (A)

Department of Social Psychology and Quantitative Psychology, Faculty of Psychology, University of Barcelona, 08035 Barcelona, Spain.
CIBER en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Noelia Llorens (N)

Delegación del Gobierno Para el Plan Nacional Sobre Drogas, Ministerio de Sanidad, Gobierno de España, 28008 Madrid, Spain.

Juan Hoyos (J)

Departamento de Salud Pública y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Gregorio Barrio (G)

CIBER en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Escuela Nacional de Salud, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Maria Jose Belza (MJ)

CIBER en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Escuela Nacional de Salud, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Lucía Cea-Soriano (L)

Departamento de Salud Pública y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.

Ariadna Angulo-Brunet (A)

Faculty of Psychology and Education Sciences, Universitat Oberta de Catalunya, Rambla del Poblenou, 08018 Barcelona, Spain.

Luis Sordo (L)

Departamento de Salud Pública y Materno-Infantil, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH